Kardigan hypertension drug tangles biomarker win with blood pressure miss in phase 2 trial
Fuente:
FierceBiotech
Kardigan’s tonlamarsen reduced a key biomarker for hypertension in a phase 2 trial, but missed the study’s other goal of significantly reducing blood pressure.